The effect of B-type brain natriuretic peptide on patients with acute decompensated heart failure coexisting with lung cancer: A randomized controlled clinical trial

Pharmazie

Volumn 69, Issue 3, 2014, Pages 212-216

  Wang, Shaojun ^a   Qu, Xiufen ^a   Qu, Yuanyuan ^a   Yu, Yanwei ^a   Feng, Wei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; RECOMBINANT HUMAN B TYPE NATRIURETIC PEPTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSPNEA; ECHOCARDIOGRAPHY; EMERGENCY PATIENT; FATIGUE; FEMALE; FOLLOW UP; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LEG EDEMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DYSPNEA; EDEMA; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMODYNAMICS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXYGEN; RECOMBINANT PROTEINS; SURVIVAL;

EID: 84897142461     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3738     Document Type: Article

References (19)

1. Attar EC, Ervin T, Janicek M, Deykin A, Godleski J (2000) Side effects of chemotherapy. J Clin Oncol 18: 697-697.
2. Bhat G, Costea A (2003) Reversibility of medically unresponsive pulmonary hypertension with nesiritide in a cardiac transplant recipient. ASAIO J 49: 608-610. (Pubitemid 37129288)
3. Bründler H, Chen S, Perruchoud A (1985) Right heart catheterization in the pre-operative evaluation of patients with lung cancer. Respiration 48: 261-268. (Pubitemid 16236749)
4. Braunwald E, Bristow MR (2000) Congestive heart failure: fifty years of progress. Circulation 102: Iv14-Iv23.
5. Burger AJ, Burger MR (2005) Nesiritide: past, present, and future. Minerva Cardioangiol 53: 509-522. (Pubitemid 43089158)
6. Burjonroppa SC, Tong AT, Xiao L-C, Johnson MM, Yusuf SW, Lenihan DJ (2007) Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol 30: 287-293. (Pubitemid 46884150)
7. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang C-s, Neibaur M (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. New Engl J Med 343: 246-253. (Pubitemid 30490392)
8. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 29: 2388-2442.
9. Dudgeon DJ, Lertzman M (1998) Dyspnea in the advanced cancer patient. J Pain Symptom Manage 16: 212-219. (Pubitemid 28478234)
10. Ezekowitz JA, Hernandez AF, O'Connor CM, Starling RC, Proulx G, Weiss MH, Bakal JA, Califf RM, McMurray JJ, Armstrong PW (2012) Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. J Am Coll Cardiol 59: 1441-1448.
11. Liu SQ, Xie HW, Yan HY, Lu YQ, Wang LX (2012) Recombinant B-type natriuretic peptide nesiritide attenuates vascular remodelling by reducing plasma aldosterone in rabbits. Heart Lung Circ 21: 551-555.
12. Michaels AD, Chatterjee K, De Marco T (2005) Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail 11: 425-431.
13. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJV, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh B-H, Pereira NL, Ponikowski P, Tang WHW, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM (2011) Effect of nesiritide in patients with acute decompensated heart failure. New Engl J Med 365: 32-43.
14. Reichert S, Ignaszewski A (2008) Molecular and physiological effects of nesiritide. Can J Cardiol 24 Suppl B: 15B-18B.
15. Scroggins N, Edwards M, Delgado R, 3rd (2005) Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure. Congest Heart Fail 11: 311-314.
16. Solin P, Bergin P, Richardson M, Kaye DM, Walters EH, Naughton MT (1999) Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 99: 1574-1579. (Pubitemid 29152924)
17. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135:1429-1435.
18. Young JB, Abraham W, Stevenson L, Horton D, Elkayam U, Bourge R (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure-A randomized controlled trial. JAMA 287:1531-1540. (Pubitemid 34269998)
19. Zakir RM, Berkowitz RL, Saric M, Ashtyani H (2005) A comparison of nesiritide vs. epoprostenol in a patient with precapillary pulmonary hypertension due to scleroderma complicated by postcapillary pulmonary hypertension. Congest Heart Fail 11:331-334.